Should Medicare Cover Alzheimer’s Screening Tests Under the Proposed Bill?

Learn what the Alzheimer's screening bill covers, its limits, and what to ask your doctor before you pay for a test.

Yes — under the proposed bill, Medicare should be able to cover FDA-approved blood tests for early Alzheimer's detection. The bipartisan Alzheimer's Screening and Prevention Act would create a Medicare coverage pathway for those tests. Blood biomarker tests are blood draws that measure Alzheimer's-linked proteins.

The Alzheimer's Association reports the bill would open Medicare coverage for FDA-approved or cleared blood biomarker tests (the introduction announcement). Right now, blood tests used before symptoms are treated as uncovered preventive services. The Alzheimer's Impact Movement reports that current law blocks Medicare from covering any Alzheimer's screening test, a barrier only Congress can fix (the early-screening update).

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What would the bill change?

The bill gives Medicare legal authority it now lacks. It creates a coverage pathway for blood tests cleared or approved by the FDA. Doctors could then order a simple blood draw instead of sending every patient for imaging or spinal testing.

Coverage would run through Medicare's normal evidence-based process. That means officials review benefits, risks, and appropriate use before paying broadly. Families would get a clearer yes-or-no rule instead of case-by-case denials.

Who could benefit from testing?

The main group is Medicare beneficiaries worried about memory loss or early dementia. A blood test can simplify the first step of evaluation for people age 55 and older with cognitive signs. The Association of Health Care Journalists reports the FDA cleared two blood-based tests in 2025 for that symptomatic group (the screening coverage explainer).

Earlier answers help families plan care, safety, work, and finances. They also help doctors rule out reversible causes and refer the right patients to specialists. For people who qualify for treatment, documented amyloid evidence can speed decisions.

Why doesn't the bill guarantee coverage?

The bill authorizes coverage but does not order it. The Alzheimer's Impact Movement notes it only lets Medicare cover early screening through its evidence-based process, while current cleared tests remain labeled for symptomatic evaluation (the early-screening update).

That limit matters for healthy adults without symptoms. A test result without symptoms is harder to interpret and act on. False positives can cause worry, extra scans, and unneeded referrals.

What can you do now?

Use symptoms and family history to guide your next visit. Bring notes about onset, frequency, and daily effects. Ask whether a cognitive exam, lab work, or specialist referral fits first.

Keep the bill in perspective while you wait. Track whether Medicare issues a coverage decision for your situation. Save test offers, prices, and coverage letters for later review.

  • Write down memory changes, dates, medicines, sleep issues, and questions
  • Ask your clinician what a blood biomarker result would change for you
  • Ask about cost before testing, since non-covered screening is usually self-pay
  • If referred, ask what follow-up test confirms the result

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.